Corvus Pharmaceuticals (CRVS) Other Operating Expenses (2016 - 2026)

Corvus Pharmaceuticals' Other Operating Expenses history runs 6 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Other Operating Expenses rose 544.82% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $2.7 million (up 220.68% YoY), while the FY2022 annual figure was $22000.0, changed N/A from the prior year.
• Other Operating Expenses for Q1 2026 stood at $4.2 million, up from -$617000.0 in the prior quarter.
• The five-year high for Other Operating Expenses was $4.2 million in Q1 2026, with the low at -$946000.0 in Q1 2025.
• The 3-year median for Other Operating Expenses is -$617000.0 (2025), against an average of $412285.7.
• The sharpest annual moves came in 2025 and 2026: Other Operating Expenses plunged 139.16% in 2025, then surged 544.82% in 2026.
• Corvus Pharmaceuticals' Other Operating Expenses stood at -$776000.0 in 2024, then gained by 20.49% to -$617000.0 in 2025, then soared by 782.01% to $4.2 million in 2026.
• Business Quant data shows CRVS's Other Operating Expenses at $4.2 million in Q1 2026, -$617000.0 in Q3 2025, and -$848000.0 in Q2 2025.